We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
We have to do our bit. It may end up being a combination of the universities we worked with in 2015. However, our increased production of Modern Water reagents mean Integumen are working on both Labskin and the water contamination detection bacteria to do our bit in this crisis.
Keep the community posted on whether or not the pro-bono tests are accepted by Government. I can't see who else has the ability to do those tests including an element of AI to speed up the results. Super initiative that will position the company favourably.
In an extract from my comment in a previous comment I stated that "-our [Integumen's] AI division is exploring options to develop data analytic tools for Modern Water's monitoring equipment-" I refer to the fact that we are exploring options and one of these options is whether we can make use of our AI tools, that have been successful in identifying bacteria in seconds, instead of 24-72 hours.
Integumen's Labskin in 2015 has worked and been successful on Ebola and HSV-1, (hxxps://www.labskin.co.uk/wp-content/uploads/2018/10/2015-A-novel-antiviral-compound-inhibits-diverse-viral-infections.pdf). These same techniques are working on projects that include malaria, mastitis and legionella. Rinocloud (AI) has already completed a 4 year study that successfully delivered a solution that could be adopted into Modern Water equipment that are already installed in hundreds of places where we can test. Labskin has offered pro-bono access to Category 3 laboratories to test SARS-CoV-2 on the laboratory grown skin for the following tests to prove
1. If the virus is transmissible from surfaces to airways via skin by measuring its viability when recovered from surface(s) to skin.
2. Show that sanitizers kill the virus on the skin (this is anecdotally assumed to be correct based on WHO research on other bacteria, but not, as far as we know, proved for COVID).
3. Show the reduction of titer and/or virulence.
Tests for the virus in wastewater could be an early indication on hotspots and could reduce the need for individual testing of the entire population. By using a combination of virus detection in faecal matter and geolocation and AI to identify local breakout areas, concentration of resources could be allocated. This continues to be a focus of our development program.
There are amazing technologies that already exist, within individual companies, which is why ecowaterOS was setup. Collaboration, joint development and partnership provide access to an integrated technology platform where the potential for results are achievable much quicker than as standalone development programs.
In answer to a comment on the Modern Water forum I posted the following in two comments:
I am replying to your comments because you raise many valid points. Bear wit me as i am restricted under MAR and AIM rules as to what can be said, so I will refer to RNS's that have been issued.
I agree 100% that historically the company has been unsuccessful in achieving it's original aims set out at the IPO. A lot of investment went into the technology and the IP remains secure. The Board of Directors have been instrumental in altering the entire business model and this was outlined in the RNS of the 198th March. My comments, as CEO of Integumen (SKIN) were as follows:
"We are delighted to announce the continued expansion of our laboratories and to be able to provide European bacteria reagent manufacturing capacity and logistic support to Modern Water's sales, marketing and distribution in the US, EU, China and Japan. In addition to production of the bacteria reagents, our AI division is exploring options to develop data analytic tools for Modern Water's monitoring equipment, with the potential to add higher-value bolt-on real-time alert services leading to increased revenue per client"
The CEO's comments also acknowledged the alteration in business model by the agreement:
"This Agreement is a water-shed moment for Modern Water. We are moving from a self-contained production, sales, marketing and distribution company to a collaborative, cooperation and partnership business model. This immediately gives Modern Water access to state-of-the art laboratories in the UK without the need for capital expenditure. Integumen's superior development and manufacturing capabilities will enable us rapidly to grow our existing network of sales, marketing and distribution channels, delivering the quality of product we are synonymous with, whilst lowering operational costs."
That same RNS confirmed: "The Agreement enables the Company to fulfill an order backlog of approximately $665,000 which it is not currently able to meet."
The headline of RNS of the 30th "Orders of water contamination detection consumables up 46% in Q1 2020 compared to Q1 2019" suggests that COVID19 has indeed placed a higher burden on demand for monitoring equipment consumables and the agreement with Integumen, even amongst the lockdown of many companies, is being met as the supplies are essential materials in the fight to contain the public health crisis.
Next Comments to follow